Mesalazine-induced nephrolitiasis and crystalluria.

Rafel M Prieto, Francesca Julià, Flor A Ordoñez, Antonia Costa-Bauzà, Andrea Cabeza, Myriam Muñoz, Felix Grases

Abstract readCase Reports

In one paragraph

Article in Urology case reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Rafel M PrietoResearch Laboratory on Renal Lithiasis and Pathological Calcification, IUNICS-IdISBa, University of Balearic Islands, Palma, Spain.

Francesca JuliàResearch Laboratory on Renal Lithiasis and Pathological Calcification, IUNICS-IdISBa, University of Balearic Islands, Palma, Spain.

Flor A OrdoñezPediatric Nephrology, Clinical Management Area of Childhood and Adolescence, Central University Hospital of Asturias, Oviedo, Spain.

Antonia Costa-BauzàResearch Laboratory on Renal Lithiasis and Pathological Calcification, IUNICS-IdISBa, University of Balearic Islands, Palma, Spain.

Andrea CabezaPediatric Nephrology, Clinical Management Area of Childhood and Adolescence, Central University Hospital of Asturias, Oviedo, Spain.

Myriam MuñozPediatric Nephrology, Clinical Management Area of Childhood and Adolescence, Central University Hospital of Asturias, Oviedo, Spain.

Felix GrasesResearch Laboratory on Renal Lithiasis and Pathological Calcification, IUNICS-IdISBa, University of Balearic Islands, Palma, Spain.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Mesalazine (5-aminosalicylic acid) is an anti-inflammatory drug used for autoimmune diseases. Premature release mesalazine in the small intestine or proximal colon can increase systemic absorption. A 13-year-old with ulcerative colitis treated with Pentasa® at 2 g mesalazine/day developed stones when this dose was doubled. Mesalazine has low water solubility; higher doses raise urinary supersaturation, promoting epitaxial growth of mesalazine crystals that form a stone. In children, lower body weight and reduced urine volume increase this risk. Dose adjustment and adequate hydration are essential, as low urine output raises mesalazine concentration and favors crystallization. Increased fluid intake is strongly recommended.

Identifiers

PMID42375674

DOI10.1016/j.eucr.2026.103513

PMCPMC13311289

What OpenQuestion holds

Textmetadata

LicenceCC BY-NC-ND

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.